CL2013003365A1 - Formulacion farmaceutica que comprende diacilglicerol y/o tocoferol, fosfatidilcolina, solvente mono-alcoholico organico biocompatible que comprende etanol, solvente polar, y un analogo de somatostatina como principio activo; proceso para prepararla; kit farmaceutico; uso en el tratamiento de acromegalia y canceres, entre otros. - Google Patents
Formulacion farmaceutica que comprende diacilglicerol y/o tocoferol, fosfatidilcolina, solvente mono-alcoholico organico biocompatible que comprende etanol, solvente polar, y un analogo de somatostatina como principio activo; proceso para prepararla; kit farmaceutico; uso en el tratamiento de acromegalia y canceres, entre otros.Info
- Publication number
- CL2013003365A1 CL2013003365A1 CL2013003365A CL2013003365A CL2013003365A1 CL 2013003365 A1 CL2013003365 A1 CL 2013003365A1 CL 2013003365 A CL2013003365 A CL 2013003365A CL 2013003365 A CL2013003365 A CL 2013003365A CL 2013003365 A1 CL2013003365 A1 CL 2013003365A1
- Authority
- CL
- Chile
- Prior art keywords
- pharmaceutical formulation
- pharmaceutical
- diacylglycerol
- phosphatidylcholine
- tocopherol
- Prior art date
Links
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 title abstract 4
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 4
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 title abstract 3
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 title abstract 2
- 150000001982 diacylglycerols Chemical class 0.000 title abstract 2
- 239000002798 polar solvent Substances 0.000 title abstract 2
- 239000002904 solvent Substances 0.000 title abstract 2
- NHXLMOGPVYXJNR-ATOGVRKGSA-N somatostatin Chemical class C([C@H]1C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N1)[C@@H](C)O)NC(=O)CNC(=O)[C@H](C)N)C(O)=O)=O)[C@H](O)C)C1=CC=CC=C1 NHXLMOGPVYXJNR-ATOGVRKGSA-N 0.000 title abstract 2
- 229960001295 tocopherol Drugs 0.000 title abstract 2
- 229930003799 tocopherol Natural products 0.000 title abstract 2
- 235000010384 tocopherol Nutrition 0.000 title abstract 2
- 239000011732 tocopherol Substances 0.000 title abstract 2
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 title abstract 2
- 206010000599 Acromegaly Diseases 0.000 title 1
- 206010028980 Neoplasm Diseases 0.000 title 1
- 239000004480 active ingredient Substances 0.000 title 1
- 238000000034 method Methods 0.000 title 1
- 239000000203 mixture Substances 0.000 abstract 4
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 abstract 3
- 238000009472 formulation Methods 0.000 abstract 2
- 239000013543 active substance Substances 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 239000012530 fluid Substances 0.000 abstract 1
- 239000007788 liquid Substances 0.000 abstract 1
- 238000002483 medication Methods 0.000 abstract 1
- 238000002360 preparation method Methods 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/31—Somatostatins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
- A61K9/1274—Non-vesicle bilayer structures, e.g. liquid crystals, tubules, cubic phases or cochleates; Sponge phases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
- A61P5/46—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of glucocorticosteroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/655—Somatostatins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Endocrinology (AREA)
- Diabetes (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Dermatology (AREA)
- Dispersion Chemistry (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Immunology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Toxicology (AREA)
- Oncology (AREA)
- Child & Adolescent Psychology (AREA)
- Obesity (AREA)
- Ophthalmology & Optometry (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
Abstract
La solicitud 201303365 describe a una formulación farmacéutica que comprende una mezcla de baja viscosidad de: (a) 20-80 % en peso de por lo menos un diacilglicerol y/o un tocoferol; (b) 20-80 % en peso de por lo menos una fosfatidilcolina (PC); (c) 5-20 % en peso de por lo menos un solvente mono-alcohólico orgánico biocompatible que comprende etanol; (d) hasta 20 % en peso de un solvente polar, seleccionado desde agua, propilenglicol o mezclas de los mismos; (e) por lo menos un agente activo peptídico de análogo de somatostatina; donde la formulación farmacéutica tiene una viscosidad de 1-1.000 mPas a 20 °C; donde la relación de componentes a:b está dentro del rango 40:60 a 54:46; donde la formulación forma, o es capaz de formar, por lo menos una estructura de fase cristalina líquida luego del contacto con fluido acuoso en exceso. Además, se describe un proceso de preparación de la formulación; su uso para preparar medicamentos; y un kit farmacéutico que comprende a la formulación farmacéutica.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161489886P | 2011-05-25 | 2011-05-25 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2013003365A1 true CL2013003365A1 (es) | 2014-07-25 |
Family
ID=46456496
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2013003365A CL2013003365A1 (es) | 2011-05-25 | 2013-11-22 | Formulacion farmaceutica que comprende diacilglicerol y/o tocoferol, fosfatidilcolina, solvente mono-alcoholico organico biocompatible que comprende etanol, solvente polar, y un analogo de somatostatina como principio activo; proceso para prepararla; kit farmaceutico; uso en el tratamiento de acromegalia y canceres, entre otros. |
Country Status (37)
| Country | Link |
|---|---|
| US (3) | US11433120B2 (es) |
| EP (2) | EP4427814A3 (es) |
| JP (2) | JP6265888B2 (es) |
| KR (1) | KR102066755B1 (es) |
| CN (2) | CN103702662B (es) |
| AR (1) | AR086577A1 (es) |
| AU (2) | AU2012260821B2 (es) |
| BR (1) | BR112013030104A8 (es) |
| CA (1) | CA2836847C (es) |
| CL (1) | CL2013003365A1 (es) |
| CO (1) | CO6900117A2 (es) |
| CR (1) | CR20130653A (es) |
| CU (1) | CU20130158A7 (es) |
| DK (1) | DK2714004T3 (es) |
| DO (1) | DOP2013000275A (es) |
| EA (1) | EA036213B1 (es) |
| EC (1) | ECSP13013107A (es) |
| ES (1) | ES2984717T3 (es) |
| FI (1) | FI2714004T3 (es) |
| GT (1) | GT201300292A (es) |
| HR (1) | HRP20240781T1 (es) |
| HU (1) | HUE067389T2 (es) |
| IL (1) | IL229376B (es) |
| LT (1) | LT2714004T (es) |
| MX (1) | MX361716B (es) |
| MY (1) | MY177820A (es) |
| NI (1) | NI201300127A (es) |
| PE (1) | PE20141484A1 (es) |
| PH (1) | PH12013502550B1 (es) |
| PL (1) | PL2714004T3 (es) |
| PT (1) | PT2714004T (es) |
| RS (1) | RS65702B1 (es) |
| SG (1) | SG194865A1 (es) |
| SI (1) | SI2714004T1 (es) |
| TW (1) | TWI624271B (es) |
| WO (1) | WO2012160213A1 (es) |
| ZA (1) | ZA201309653B (es) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ551990A (en) * | 2004-06-04 | 2011-01-28 | Camurus Ab | Liquid depot formulations |
| WO2013151771A1 (en) | 2012-04-05 | 2013-10-10 | Massachusetts Institute Of Technology | Immunostimulatory compositions and methods of use thereof |
| NZ702028A (en) * | 2012-05-25 | 2016-07-29 | Camurus Ab | Somatostatin receptor agonist formulations |
| US9937164B2 (en) | 2012-07-26 | 2018-04-10 | Camurus Ab | Opioid formulations |
| MY189481A (en) | 2012-07-26 | 2022-02-16 | Camurus Ab | Opioid formulations |
| US10300145B2 (en) | 2016-07-15 | 2019-05-28 | Massachusetts Institute Of Technology | Synthetic nanoparticles for delivery of immunomodulatory compounds |
| IL265270B (en) | 2016-09-15 | 2022-09-01 | Camurus Ab | Prostacyclin analog formulations |
| JP7138626B2 (ja) * | 2016-09-27 | 2022-09-16 | カムルス エービー | アルキルアンモニウムｅｄｔａ塩を含む混合物及び製剤 |
| CA3045114A1 (en) | 2016-12-07 | 2018-06-14 | Ra Pharmaceuticals, Inc. | Modulators of complement activity |
| AR113885A1 (es) * | 2017-11-15 | 2020-06-24 | Rhythm Pharmaceuticals Inc | Formulaciones de péptidos de liberación sostenida |
| ES3035198T3 (en) | 2018-03-02 | 2025-08-29 | Elicio Therapeutics Inc | Cpg amphiphiles and uses thereof |
| CN109091451B (zh) * | 2018-09-10 | 2021-08-13 | 武汉百纳礼康生物制药有限公司 | 亲水性药物的油相液晶凝胶前体制剂及其制备方法 |
| JP2022525781A (ja) | 2019-03-20 | 2022-05-19 | マサチューセッツ インスティテュート オブ テクノロジー | 免疫細胞療法における両親媒性物質の使用およびそのための組成物 |
| EA202192919A1 (ru) | 2019-05-29 | 2022-02-18 | Камурус Аб | Композиции на основе липидов с контролируемым высвобождением |
| CN113368041B (zh) * | 2020-07-17 | 2023-01-03 | 丽珠医药集团股份有限公司 | 药物组合物、缓释制剂及其制备方法 |
| WO2022235186A1 (en) * | 2021-05-04 | 2022-11-10 | Camurus Ab | Compositions and methods for treating neuroendocrine tumors |
| WO2024263085A1 (en) * | 2023-06-20 | 2024-12-26 | Camurus Ab | Compositions and methods for treating acromegaly |
| WO2025229402A1 (en) | 2024-05-02 | 2025-11-06 | Camurus Ab | Lipid compositions and methods of use thereof |
| WO2025229403A1 (en) | 2024-05-02 | 2025-11-06 | Camurus Ab | Lipid compositions and methods of use thereof |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8865021B2 (en) * | 2003-11-07 | 2014-10-21 | Camurus Ab | Compositions of lipids and cationic peptides |
| NZ551990A (en) * | 2004-06-04 | 2011-01-28 | Camurus Ab | Liquid depot formulations |
| GB0412530D0 (en) * | 2004-06-04 | 2004-07-07 | Camurus Ab | Formulation |
| GB0417388D0 (en) | 2004-08-04 | 2004-09-08 | Camurus Ab | Composition |
| KR101234885B1 (ko) | 2004-08-04 | 2013-02-19 | 카무러스 에이비 | 비층상 분산을 형성하는 조성물 |
| EP1843746B1 (en) * | 2005-01-14 | 2011-03-16 | Camurus Ab | Somatostatin analogue formulations |
| ES2458992T3 (es) * | 2005-01-14 | 2014-05-07 | Camurus Ab | Formulaciones de análogos de GnRH |
| NZ560568A (en) * | 2005-01-21 | 2011-02-25 | Camurus Ab | Particulate compositions comprising phosphatidyl choline, diacyl glycerol or tocopherol, and a non-ionic stabilising amphiphile |
| ATE509634T1 (de) * | 2005-04-08 | 2011-06-15 | Amylin Pharmaceuticals Inc | Pharmazeutische formulierungen mit incretin- peptid und aprotisch-polarem lösungsmittel |
| US8546326B2 (en) * | 2005-06-06 | 2013-10-01 | Camurus Ab | Glp-1 analogue formulations |
| GB0711656D0 (en) * | 2007-06-15 | 2007-07-25 | Camurus Ab | Formulations |
| GB0716385D0 (en) * | 2007-08-22 | 2007-10-03 | Camurus Ab | Formulations |
| GB0815435D0 (en) * | 2008-08-22 | 2008-10-01 | Camurus Ab | Formulations |
| US8931272B2 (en) * | 2010-10-29 | 2015-01-13 | Ford Global Technologies, Llc | Method and system for limiting output of a boosted engine |
| PE20141297A1 (es) * | 2011-12-05 | 2014-10-09 | Camurus Ab | Formulaciones peptidicas robustas de liberacion controlada |
| NZ702028A (en) * | 2012-05-25 | 2016-07-29 | Camurus Ab | Somatostatin receptor agonist formulations |
| US20230285502A1 (en) * | 2016-09-07 | 2023-09-14 | Camurus Ab | Mixtures and formulations |
| JP7138626B2 (ja) * | 2016-09-27 | 2022-09-16 | カムルス エービー | アルキルアンモニウムｅｄｔａ塩を含む混合物及び製剤 |
-
2012
- 2012-05-25 CA CA2836847A patent/CA2836847C/en active Active
- 2012-05-25 RS RS20240722A patent/RS65702B1/sr unknown
- 2012-05-25 CN CN201280025151.1A patent/CN103702662B/zh active Active
- 2012-05-25 EA EA201391675A patent/EA036213B1/ru not_active IP Right Cessation
- 2012-05-25 PT PT127313153T patent/PT2714004T/pt unknown
- 2012-05-25 PL PL12731315.3T patent/PL2714004T3/pl unknown
- 2012-05-25 SG SG2013083019A patent/SG194865A1/en unknown
- 2012-05-25 MY MYPI2013004227A patent/MY177820A/en unknown
- 2012-05-25 SI SI201232066T patent/SI2714004T1/sl unknown
- 2012-05-25 HR HRP20240781TT patent/HRP20240781T1/hr unknown
- 2012-05-25 LT LTEPPCT/EP2012/059917T patent/LT2714004T/lt unknown
- 2012-05-25 FI FIEP12731315.3T patent/FI2714004T3/fi active
- 2012-05-25 KR KR1020137034307A patent/KR102066755B1/ko active Active
- 2012-05-25 TW TW101118843A patent/TWI624271B/zh active
- 2012-05-25 PE PE2013002546A patent/PE20141484A1/es active IP Right Grant
- 2012-05-25 CN CN201810174910.XA patent/CN108283619B/zh active Active
- 2012-05-25 DK DK12731315.3T patent/DK2714004T3/da active
- 2012-05-25 HU HUE12731315A patent/HUE067389T2/hu unknown
- 2012-05-25 MX MX2013013401A patent/MX361716B/es active IP Right Grant
- 2012-05-25 AU AU2012260821A patent/AU2012260821B2/en active Active
- 2012-05-25 BR BR112013030104A patent/BR112013030104A8/pt not_active Application Discontinuation
- 2012-05-25 WO PCT/EP2012/059917 patent/WO2012160213A1/en not_active Ceased
- 2012-05-25 US US14/117,994 patent/US11433120B2/en active Active
- 2012-05-25 ES ES12731315T patent/ES2984717T3/es active Active
- 2012-05-25 EP EP24175676.6A patent/EP4427814A3/en active Pending
- 2012-05-25 JP JP2014511911A patent/JP6265888B2/ja active Active
- 2012-05-25 EP EP12731315.3A patent/EP2714004B1/en active Active
- 2012-05-28 AR ARP120101869A patent/AR086577A1/es unknown
-
2013
- 2013-11-11 IL IL22937613A patent/IL229376B/en active IP Right Grant
- 2013-11-22 NI NI201300127A patent/NI201300127A/es unknown
- 2013-11-22 DO DO2013000275A patent/DOP2013000275A/es unknown
- 2013-11-22 CL CL2013003365A patent/CL2013003365A1/es unknown
- 2013-11-22 GT GT201300292A patent/GT201300292A/es unknown
- 2013-11-25 CU CU2013000158A patent/CU20130158A7/es unknown
- 2013-12-09 PH PH12013502550A patent/PH12013502550B1/en unknown
- 2013-12-12 CR CR20130653A patent/CR20130653A/es unknown
- 2013-12-20 CO CO13297046A patent/CO6900117A2/es unknown
- 2013-12-20 ZA ZA2013/09653A patent/ZA201309653B/en unknown
- 2013-12-24 EC ECSP13013107 patent/ECSP13013107A/es unknown
-
2016
- 2016-04-06 AU AU2016202156A patent/AU2016202156B2/en active Active
-
2017
- 2017-11-29 JP JP2017228735A patent/JP6415673B2/ja active Active
-
2021
- 2021-06-17 US US17/350,363 patent/US20210308226A1/en not_active Abandoned
-
2024
- 2024-09-18 US US18/889,001 patent/US20250121035A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2013003365A1 (es) | Formulacion farmaceutica que comprende diacilglicerol y/o tocoferol, fosfatidilcolina, solvente mono-alcoholico organico biocompatible que comprende etanol, solvente polar, y un analogo de somatostatina como principio activo; proceso para prepararla; kit farmaceutico; uso en el tratamiento de acromegalia y canceres, entre otros. | |
| BR112015025172A2 (pt) | composição farmacêutica | |
| PE20141297A1 (es) | Formulaciones peptidicas robustas de liberacion controlada | |
| AR083016A1 (es) | Formulaciones liquidas para la agricultura con una mejor estabilidad | |
| AR106049A1 (es) | Formulaciones de liberación controlada | |
| BRPI0511807C1 (pt) | pré-formulação, processo de formação de uma pré-formulação e uso da mesma | |
| BR112017013471A2 (pt) | Pré-formulação, formulação farmacêutica, composição de depósito, métodos para administração de um agente bioativo a um organismo humano ou não humano, para preparação de uma composição cristalina líquida, para tratamento ou profilaxia de um indivíduo animal não humano ou humano, para administração de uma pré-formulação para um sujeito que dela necessita, processo para formação de uma pré- formulação, uso de uma mistura cristalina não líquida de baixa viscosidade, dispositivo de administração pré-preenchido, e, kit. | |
| PE20191714A1 (es) | Nanoparticula polimerica de finasterida y minoxidil, proceso de preparacion, suspension acuosa conteniendo la misma, composicion farmaceutica, y su uso | |
| MX2013007807A (es) | Emulsiones de aceite/agua que comprenden alcanos semifluorados. | |
| GT201300137A (es) | Derivados de imidazo [1,2-b] piridazina e imidazo [4,5-b] piridina como inhibidores de jak | |
| DK1845942T3 (da) | GNRH-analogformuleringer | |
| BR112012015433B8 (pt) | composição farmacêutica substancialmente anidra para aplicação cutânea | |
| MX2019003520A (es) | Mezclas y formulacions que comprenden una sal de alquil amonio de acido etilendiaminotetraacetico (edta). | |
| UY28366A1 (es) | Compuestos químicos | |
| AR099097A1 (es) | SUSPOEMULSIÓN ACUOSA QUE CONTIENE l-CIALOTRINA Y MÉTODOS PARA PRODUCIR Y USAR LA MISMA | |
| TN2014000483A1 (en) | Somatostatin receptor agonist formulations | |
| CO2018006865A2 (es) | Métodos y composiciones para tratar una corriente que comprende petróleo crudo y agua | |
| AR105691A1 (es) | Método, composición y conjunto de elementos para tratar la disfunción eréctil | |
| CO2018000526A2 (es) | Concentrado que contiene alprostadil | |
| HK1239563A1 (en) | Controlled-release formulations | |
| CO2018000525A2 (es) | Concentrado que contiene alprostadil | |
| PE20180458A1 (es) | Metodo y composicion y kit para tratar la disfuncion erectil | |
| AR100815A1 (es) | Formulaciones parasiticidas transdérmicas, método, uso |